Loading clinical trials...
Loading clinical trials...
This study is investigate the influence of severe hepatic impairment on the pharmacokinetics of acalabrutinib and its metabolite.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Acerta Pharma BV
Collaborators
NCT06342713 · Healthy Participants, Healthy Subjects, and more
NCT06014515 · Healthy Subjects, Cardiovascular Disease
NCT07324616 · Hepatic Impairment (HI)
NCT07181369 · Healthy Subjects, Cold Urticaria, and more
NCT07023354 · Healthy, Hepatic Impairment
Research Site
Miami, Florida
Research Site
Orlando, Florida
Research Site
Knoxville, Tennessee
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions